Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic; Charles University, Faculty of Medicine in Hradec Králové, Šimkova 870, Hradec Králové 500 03, Czech Republic.
Institute for Clinical and Experimental Medicine, Department of Cardiology, Vídeňská 1958/9, Prague 4 140 21, Czech Republic.
Int J Cardiol. 2018 Nov 1;270:325-330. doi: 10.1016/j.ijcard.2018.06.009. Epub 2018 Jun 6.
Cardiac resynchronization therapy (CRT) improves symptoms of heart failure (HF), morbidity and mortality in selected population. The aim of the study was to investigate the impact of cardiac magnetic resonance (CMR)-guided left ventricular (LV) lead placement on clinical outcomes and LV reverse remodelling in CRT recipients.
Patients with CRT indication were randomized for CMR-guided (CMR group) or electrophysiologically guided (EP group) LV lead placement between 2011 and 2014. The target site in the CMR group was defined as the most delayed, scar-free, in the EP group as the site with the longest interval between the QRS onset and local electrogram. The primary endpoint was a combination of cardiovascular death or HF hospitalization. Secondary endpoints were New York Heart Association (NYHA) Class improvement ≥1, LV endsystolic diameter reduction >10%, B-type natriuretic peptide reduction by ≥30%.
A total of 99 patients (47 in the CMR and 52 in the EP group) were enrolled. During a median follow-up of 47 months, primary composite endpoint occurred in 5 patients in the CMR group and 14 patients in the EP group (HR = 0.46; 95% CI: 0.16-1.32). Patients with left bundle branch block and NYHA Class >2 had better clinical outcome in the CMR group (HR = 0.09; 95% CI: 0.01-0.75).
The use of CMR did not result in significant reduction of combined endpoint of cardiovascular death or HF hospitalization in the total study population. Significant clinical benefit from CMR-guided procedure was observed in a subgroup of optimum CRT candidates with advanced HF.
心脏再同步治疗(CRT)可改善心力衰竭(HF)患者的症状、发病率和死亡率,适用于特定人群。本研究旨在探讨心脏磁共振(CMR)指导下左心室(LV)导线植入对 CRT 患者临床结局和 LV 逆重构的影响。
2011 年至 2014 年间,对符合 CRT 适应证的患者进行随机分组,行 CMR 指导(CMR 组)或电生理指导(EP 组)LV 导线植入。CMR 组的目标部位定义为延迟最明显、无瘢痕的部位,EP 组的目标部位定义为 QRS 起始与局部电图之间间隔最长的部位。主要终点为心血管死亡或 HF 住院的联合终点。次要终点为纽约心脏病协会(NYHA)心功能分级改善≥1 级、LV 收缩末期直径减少≥10%、B 型利钠肽减少≥30%。
共纳入 99 例患者(CMR 组 47 例,EP 组 52 例)。中位随访 47 个月期间,CMR 组 5 例患者和 EP 组 14 例患者发生主要复合终点(HR=0.46;95%CI:0.16-1.32)。左束支传导阻滞和 NYHA 心功能分级>2 的患者在 CMR 组的临床结局更好(HR=0.09;95%CI:0.01-0.75)。
在整个研究人群中,CMR 的使用并未显著降低心血管死亡或 HF 住院的联合终点。在 HF 晚期的 CRT 优化候选人群亚组中,CMR 指导的程序具有显著的临床获益。